NEC OncoImmunity AS  products

Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in immuno-oncology and the rapid advances in next generation sequencing (NGS), opens up exciting new opportunities to harness neoantigens for their therapeutic and biomarker potental in cancer immunotherapy. NEC OncoImmunty uses a powerful artificial intelligence (AI) engine to predict from next generation sequencing data, true neoantigens for personalized cancer immunotherapy.